Corporate

Johnson & Johnson (NYSE: JNJ) today announced an investment of more than $2 billion to build a state-of-the-art biologics manufacturing facility in Wilson, North Carolina. The new facility will expand production of the Company’s portfolio and pipeline of innovative biologics in support of Johnson & Johnson’s broader plan to advance more than 70 novel therapy and product expansion filings and launches by the end of the decade.

Approximately 83% of Current Claimants and the Future Claims Representative Support the Proposed Bankruptcy Plan Red River Increased its Settlement Commitment by $1.75 Billion to Approximately $8 Billion

The Plan would resolve 99.75% of all pending talc lawsuits against Johnson & Johnson and its affiliates in the United States

Acquisition strengthens Johnson & Johnson’s commitment to innovation in prostate cancer and deepens pipeline of next-generation antibody drug conjugates and targeted oncologic therapeutics

Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson & Johnson’s Commitment to Oncology Innovation Novel Technology Platform Sets Stage for the Development of Next Generation ADCs and Targeted Oncologic Therapeutics